Cost-Effectiveness Of Ombitasvir/Paritaprevir/Ritonavir With Or Without Dasabuvir For The Treatment Of Chronic Hepatitis C Patients Infected With Genotype 1 Or 4 In France

Treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin (OBV/PTV/r±DSV±R) achieved high sustained virologic response rates (SVR). We evaluated long-term clinical and economic outcomes of OBV/PTV/r±DSV±R compared with other antiviral treatments for treatment-naïve and -experienced chronic hepatitis C (CHC) patients infected with genotype-1 (GT1) or genotype-4 (GT4) in France. A Markov cohort simulation model for the French health...